enGene names new board chairman ahead of planned BLA filing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- Americold to wind down Ahold Delhaize facilities, take $305M charge
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Did Google and Tesla just break AI trade’s bull case?
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
July 16, 2026 8:00 AM EDTMichael Heffernan assumes the role of Chairman of the Board
Dr. Richard Glickman to step down
Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026
Initiation of BLA submission for detalimogene planned for 2H 2026
Potential FDA approval of detalimogene in 2027
BOSTON & MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential regulatory milestones and to support commercial readiness for... More
